{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:58:27Z","timestamp":1792785507295,"version":"4.5.0"},"reference-count":105,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft","award":["JU2859\/7-4"],"award-info":[{"award-number":["JU2859\/7-4"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Deutsche Forschungsgemeinschaft","award":["JU2859\/9-1"],"award-info":[{"award-number":["JU2859\/9-1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bausteinprogramm of the Medical Faculty, Ulm University","id":[{"id":"https:\/\/ror.org\/032000t02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/17460441.2026.2716800","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:48:40Z","timestamp":1786693720000},"page":"1143-1157","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Advances in antisense technology for cardiovascular drug discovery: from gene silencing to therapeutics"],"prefix":"10.1080","volume":"21","author":[{"given":"Deung-Dae","family":"Park","sequence":"first","affiliation":[{"name":"University of Ulm","place":["Ulm, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"B\u00fchler","sequence":"additional","affiliation":[{"name":"University of Ulm","place":["Ulm, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sch\u00f6llhorn","sequence":"additional","affiliation":[{"name":"University of Ulm","place":["Ulm, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Just","sequence":"additional","affiliation":[{"name":"University of Ulm","place":["Ulm, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"World Health O. Cardiovascular diseases (CVDs). World Health Organization. 2025 [cited 2025 Jul 31]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-%28cvds%29"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07487-w"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70342"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114196"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105654"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3765"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa299"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102133"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000418"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905239"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04408-4"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1210"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky397"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1089\/oli.2006.16.169"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.04.013"},{"key":"e_1_3_5_19_1","volume-title":"LEQVIO (inclisiran) prescribing information","author":"U.S. Food and Drug Administration","year":"2021","unstructured":"U.S. Food and Drug Administration. LEQVIO (inclisiran) prescribing information. Silver Spring (MD): U.S. Food and Drug Administration; 2021."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00499-9"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.01.028"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013243"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2018.00060"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247005"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.029"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14136"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3860"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.04.028"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2017.07.003"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108625"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.04.024"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-24.3.194"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-1221-6_9"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw533"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf1475"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai9118"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa898"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.001904"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076781"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065192"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.05.024"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.002"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2014.0506"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv143"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3948"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/25.22.4429"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(99)00140-2"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802607780487713"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.774366"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi0485732"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku142"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)88650-7"},{"issue":"5","key":"e_1_3_5_53_1","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias N","year":"2002","unstructured":"Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1(5):347\u2013355.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7684856"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg356"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00551"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab047"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M400492-JLR200"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60284-X"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.26"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab820"},{"key":"e_1_3_5_62_1","unstructured":"ClinicalTrials.gov. A study of AZD8233 in participants with dyslipidemia. ClinicalTrials.gov. 2020."},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16046"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12866"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0623"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.012401"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2016.12.003"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1621838"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-021-00439-4"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00898-0"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2307798120"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.01.005"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2025.06.004"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00642-7"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-0016(03)00149-7"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01830-2"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00703.2004"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-018-9785-1"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)35353-4"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2017.06.003"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21682-7"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2025.03.019"},{"key":"e_1_3_5_83_1","volume-title":"Assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on Major cardiovascular events in patients with CVD (Lp(a)horizon) (NCT04023552)","author":"ClinicalTrials.gov","year":"2019","unstructured":"ClinicalTrials.gov. Assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on Major cardiovascular events in patients with CVD (Lp(a)horizon) (NCT04023552). Bethesda (MD): U.S. National Library of Medicine (NLM); 2019."},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715944"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402309"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400201"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa689"},{"key":"e_1_3_5_88_1","unstructured":"Pfizer I Ionis Pharmaceuticals I. Pfizer and Ionis announce discontinuation of vupanorsen clinical development program. 2022. Press release."},{"key":"e_1_3_5_89_1","volume-title":"KYNAMRO (mipomersen sodium) injection, for subcutaneous use: prescribing information (initial U.S. Approval: 2013)","author":"U.S. Food and Drug Administration","year":"2013","unstructured":"U.S. Food and Drug Administration. KYNAMRO (mipomersen sodium) injection, for subcutaneous use: prescribing information (initial U.S. Approval: 2013). Silver Spring (MD): U.S. Food and Drug Administration; 2013."},{"key":"e_1_3_5_90_1","volume-title":"KYNAMRO (mipomersen sodium) injection, for subcutaneous use: prescribing information","author":"U.S. Food and Drug Administration","year":"2019","unstructured":"U.S. Food and Drug Administration. KYNAMRO (mipomersen sodium) injection, for subcutaneous use: prescribing information. Silver Spring (MD): U.S. Food and Drug Administration; 2019."},{"key":"e_1_3_5_91_1","volume-title":"TEGSEDI (inotersen) injection, for subcutaneous use: prescribing information","author":"U.S. Food and Drug Administration","year":"2018","unstructured":"U.S. Food and Drug Administration. TEGSEDI (inotersen) injection, for subcutaneous use: prescribing information. Silver Spring (MD): U.S. Food and Drug Administration; 2018."},{"key":"e_1_3_5_92_1","volume-title":"TEGSEDI (inotersen) injection, for subcutaneous use: prescribing information","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. TEGSEDI (inotersen) injection, for subcutaneous use: prescribing information. Silver Spring (MD): U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"e_1_3_5_94_1","unstructured":"ClinicalTrials.gov. CARDIO-TTRansform (NCT04136171). ClinicalTrials.gov. 2019."},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"},{"key":"e_1_3_5_96_1","volume-title":"AMVUTTRA (vutrisiran) injection, for subcutaneous use: Prescribing Information","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. AMVUTTRA (vutrisiran) injection, for subcutaneous use: Prescribing Information. Silver Spring (MD): U.S. Food and Drug Administration; 2025."},{"key":"e_1_3_5_97_1","unstructured":"ClinicalTrials.gov. ORION-4 (NCT03705234). ClinicalTrials.gov. 2018."},{"key":"e_1_3_5_98_1","article-title":"US FDA approves expanded indication for Novartis Leqvio\u00ae (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease","author":"Novartis","year":"2023","unstructured":"Novartis. US FDA approves expanded indication for Novartis Leqvio\u00ae (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease. Novartis Media Rel. 2023 Jul 10 [accessed 2026 Aug 10]. Available from: https:\/\/www.novartis.com\/us-en\/news\/media-releases\/us-fda-approves-expanded-indication-novartis-leqvio-inclisiran-include-treatment-adults-high-ldl-c-and-who-are-increased-risk-heart-disease","journal-title":"Novartis Media Rel"},{"key":"e_1_3_5_99_1","unstructured":"Alnylam Pharmaceuticals I. Alnylam announces FDA approval of AMVUTTRA (vutrisiran) the first RNAi therapeutic to reduce cardiovascular Death hospitalizations and urgent heart failure visits in adults with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Press release (investors). 2025. Available from: https:\/\/investors.alnylam.com\/press-release?id=28831"},{"key":"e_1_3_5_100_1","volume-title":"HELIOS-B: a study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (NCT04153149). ClinicalTrials.Gov","author":"ClinicalTrials.gov","year":"2019","unstructured":"ClinicalTrials.gov. HELIOS-B: a study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (NCT04153149). ClinicalTrials.Gov. Bethesda (MD): U.S. National Library of Medicine (NLM); 2019."},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1191-6"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/169775"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2024.12.009"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102186"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf392"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab442"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102208"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2026.2716800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17460441.2026.2716800","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2026.2716800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:36:20Z","timestamp":1790865380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2026.2716800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":105,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/17460441.2026.2716800"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2026.2716800","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}